Benlysta's Broad Label Prepares The Way For A New Blockbuster
Executive Summary
The broad labeling that FDA approved for Benlysta (belimumab), the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.You may also be interested in...
Your First Drug's Approved and Launched...Now What?
Industry Ignored In Dispute Over UK Retailer’s ‘Weight Management’ Claim
Need a specific report? 1000+ reports available
Buy Reports